Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy With 177Lu-EB-FAPI
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
FAP is a fibroblast activation protein and overexpressed in many tumor tissues. This study is
intended to conduct preliminary clinical transformation and internal irradiation dosimetry
research on 177Lu-EB-FAPI--a new 177Lu therapeutic drug modified by Evans Blue (EB) for the
first time in the world.